
Release date: 2025-12-31 11:57:19 Article From: Lucius Laos Recommended: 125
Ivosidenib, either as a monotherapy or in combination with azacitidine, is indicated for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients aged ≥ 75 years old, or those who are ineligible for certain cancer treatments (e.g., intensive chemotherapy) due to other health conditions.
The Ivosidenib produced by Lucius Pharmaceutical Co., Ltd. is commonly available in a packaging specification of 250 mg × 60 tablets per box. Its market price is not fixed and is usually affected by various factors such as regional differences, medical insurance policies, procurement channels, drug batches, and market supply and demand. It is recommended to inquire about the real-time price through medical institutions, designated pharmacies or official channels.
For more specific information about Ivosidenib, you can contact the official customer service of Lucius Pharmaceutical for free consultation.
Ivosidenib has been approved for the treatment of adult cancer patients harboring specific IDH1 gene mutations, including the following indications:
For newly diagnosed AML patients aged ≥ 75 years old, or those who are unable to receive intensive induction chemotherapy due to health status, it can be administered alone or in combination with azacitidine.
For patients with relapsed or refractory disease after prior treatment.
For adult patients with metastatic cholangiocarcinoma who have received prior treatment.
For patients with relapsed disease or those unresponsive to previous therapies.
In addition, Ivosidenib is currently under clinical research for the treatment of other cancer types.
1. Take Ivosidenib strictly in accordance with the instructions provided by your healthcare provider.
2. Do not adjust the dosage or discontinue Ivosidenib without consulting your healthcare provider first.
3. Take Ivosidenib once daily at approximately the same time each day.
4. Swallow Ivosidenib tablets whole. Do not split, crush or chew the tablets.
5. Ivosidenib may be taken with or without food.
6. Do not take Ivosidenib with a high-fat meal. Examples of a high-fat meal include: 2 fried eggs with butter, 2 strips of bacon, 2 slices of buttered white bread, 1 croissant, 1 slice of cheese, and 8 ounces (approximately 240 mL) of whole milk (totaling about 1000 kilocalories and 58 grams of fat).
7. If vomiting occurs after taking a dose of Ivosidenib, do not take an extra dose. Simply take the next scheduled dose at your usual time.
8. If you miss a dose of Ivosidenib or fail to take it at the usual time, take the missed dose as soon as possible, provided that there is an interval of at least 12 hours before the next scheduled dose. Resume your normal dosing schedule the following day. Do not take two doses of Ivosidenib within a 12-hour period.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:2242025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:2302025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:2432025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:2232025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:2522025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:2322025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2142025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: